Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| LL-37 (Cathelicidin) | Sermorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. | Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection. |
| Timing | Morning administration preferred for immune support. Topical application directly to wound sites. | Bedtime administration (aligns with natural nocturnal GH release). On empty stomach. |
| Cycle Duration | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. | 12-24 week cycles. Some protocols use continuous treatment. |
| Evidence Level | animal_plus_anecdotal | strong_human |
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.
Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
12-24 week cycles. Some protocols use continuous treatment.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →